Pneumocystis jirovecii pneumonia

Echinocandins

Echinocandins are a class of antifungal drugs that inhibit the synthesis of the fungal cell-wall molecule glucan. No clinical trials are available to date; however, case series and a retrospective cohort study have been published.[110]Zhang G, Chen M, Zhang S, et al. Efficacy of caspofungin combined with trimethoprim/sulfamethoxazole as first-line therapy to treat non-HIV patients with severe pneumocystis pneumonia. Exp Ther Med. 2018 Feb;15(2):1594-1601. https://www.doi.org/10.3892/etm.2017.5516 http://www.ncbi.nlm.nih.gov/pubmed/29399131?tool=bestpractice.com [111]Huang YS, Liu CE, Lin SP, et al. Echinocandins as alternative treatment for HIV-infected patients with Pneumocystis pneumonia. AIDS. 2019 Jul 1;33(8):1345-1351. https://www.doi.org/10.1097/QAD.0000000000002207 http://www.ncbi.nlm.nih.gov/pubmed/30932964?tool=bestpractice.com [112]Wang M, Lang G, Chen Y, et al. A Pilot Study of Echinocandin Combination with Trimethoprim/Sulfamethoxazole and Clindamycin for the Treatment of AIDS Patients with Pneumocystis Pneumonia. J Immunol Res. 2019;2019:8105075. https://www.doi.org/10.1155/2019/8105075 http://www.ncbi.nlm.nih.gov/pubmed/31886310?tool=bestpractice.com Echinocandins may be used increasingly in the future for the treatment of Pneumocystis pneumonia.